Low-dose lithium shows promise for protecting brain networks in early Alzheimer's

A team of researchers has begun circling back to an old psychiatric drug with fresh eyes, wondering whether it might slow the cognitive decline of Alzheimer's disease before the damage becomes irreversible. The catalyst is a recent finding: people with Alzheimer's and mild cognitive impairment have substantially lower levels of lithium in their brains than healthy individuals. When researchers depleted dietary lithium in mouse models, the animals showed accelerated buildup of tau tangles and amyloid plaques, along with loss of myelin and synapses—the hallmarks of neurodegeneration. But when they gave lithium orotate to transgenic mice engineered to develop Alzheimer's pathology, the treatment reversed cognitive deficits and reduced the underlying neuropathology. That preclinical success has prompted a closer look at how lithium might actually work.

The mechanism appears to involve the cholinergic system, the brain's acetylcholine-producing network that has long been known to deteriorate in Alzheimer's disease. In 1980, researchers discovered that lithium carbonate could inhibit serum cholinesterase, an enzyme that breaks down acetylcholine. That observation was largely forgotten, but it may be significant: several drugs that preserve acetylcholine by blocking cholinesterase—donepezil, galantamine, rivastigmine—have proven clinically useful in mild to moderate Alzheimer's. If lithium works partly through the same pathway, it could offer cognitive protection. In a pilot study of Alzheimer's patients given lithium supplementation, researchers found no significant improvement in cognition, but they did observe something intriguing: red blood cell levels of glycine and choline rose substantially. Since some small molecules move freely between blood and brain, the authors hypothesized that brain levels of these compounds rose in parallel. Increased brain choline supports cholinergic tone, while glycine modulates glutamate signaling and may offer neuroprotection.

Beyond the cholinergic angle, lithium appears to influence the structural integrity of brain networks themselves. Studies of bipolar disorder patients treated with lithium show that the drug can shift network-level communication patterns toward healthier configurations, and these changes correlate with symptom improvement. Longer exposure to lithium in older adults with bipolar disorder was associated with greater white matter integrity—a measure that typically deteriorates in dementia. In healthy volunteers, lithium treatment increased volumes of both white and gray matter. These structural changes matter because they support the local circuits and long-distance connections that underpin cognition. The authors note that if lithium can preserve white matter integrity in older people, it may help stabilize the brain networks that Alzheimer's disease gradually dismantles.

The critical question is timing. Alzheimer's pathology begins years before symptoms appear, progressing through preclinical and prodromal phases where biomarkers show early amyloid and tau dysfunction but the brain's structural disconnection remains limited. This window—before irreversible damage accumulates—may be when network-stabilizing interventions like lithium could be most effective. Trials of low-dose lithium in people with mild cognitive impairment have shown the approach is tolerable and feasible in older individuals, suggesting it is not a reckless experiment.

But the researchers are emphatic about one thing: any future trials must be conducted with meticulous safety oversight. They propose starting with low doses well below the ranges used in bipolar disorder, with slow dose increases and continuous monitoring of thyroid and kidney function. Patients would need hydration counseling and careful review of drug interactions. Researchers should systematically track tremor, gastrointestinal symptoms, confusion, movement disorders, cardiac conduction problems, and gait changes. The goal is to test whether restoring physiological lithium levels—not therapeutic doses, but the amounts the brain naturally contains—can engage the mechanisms that appear protective in animal models. If the safety profile holds and early cognitive benefits emerge, lithium could become one of the first disease-modifying approaches tested in the preclinical and prodromal stages of Alzheimer's, when the brain may still be capable of being preserved.